Health Blueprint

Back to Longevity News

News summary

Thryv Therapeutics to Participate in the UBS Global Biopharma Conference in London

Source: PR Newswire • Published: 12 Nov 2026, 16:00

Summarized by Masters of Longevity from PR Newswire.

Company reported Wave II LQT efficacy cohort fully enrolled and ASPIRE-HF plans.

Thryv Therapeutics to Participate in the UBS Global Biopharma Conference in London
Key Takeaways
  • Thryv is testing THRV-1268 in LQT2 and LQT3 patients.
  • Wave II efficacy cohort is fully enrolled with data expected.
  • ASPIRE-HF Phase 2a enrollment in Australia has not started.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickPlan Your Health Tests in Three MinutesThe free Personal Health Diagnostics Planner turns a short questionnaire into a ranked, personalised PDF: a clearer starting point for deciding which health checks deserve attention now.MoL PickCan You Really Measure Whether You’re Aging More Slowly?A younger epigenetic-age score can look like proof that an intervention is working. A major new analysis shows which clocks detect change—and why movement is not yet the same as longer healthspan.MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.